Fine Nathel et al.: Indolactam Alkaloids Supporting Information – S1

# Total syntheses of indolactam alkaloids (–)-indolactam V, (–)-pendolmycin, (–)-lyngbyatoxin A, and (–)-teleocidin A-2

Noah F. Fine Nathel,<sup>†</sup> Tejas K. Shah,<sup>†</sup> Sarah M. Bronner, and Neil K. Garg\*

Department of Chemistry and Biochemistry, University of California Los Angeles, California 90095

# Supporting Information – Table of Contents

| Materials and Methods  | S2  |
|--|-----|
| Experimental Procedures  | S3  |
| A. Optimization of the total synthesis of (–)-indolactam V (1)                 | S3  |
| B. Cross-coupling to introduce the C7 sp <sup>2</sup> -sp <sup>3</sup> linkage | S10 |
| C. Total synthesis of (–)-pendolmycin (2)                                      | S12 |
| D. Total syntheses of (-)-lyngbyatoxin A (3) and (-)-teleocidin A-2 (4)        | S16 |
| References   | S25 |
| <sup>1</sup> H NMR Spectra   | S26 |
| <sup>13</sup> C NMR Spectra  | S45 |

Materials and Methods. Unless stated otherwise, reactions were conducted in flame-dried glassware under an atmosphere of nitrogen using anhydrous solvents (either freshly distilled or passed through activated alumina columns). All commercially obtained reagents were used as received unless otherwise specified. 6-Benzyloxyindole was obtained from Combi-Blocks, Inc. Cesium fluoride (CsF), di- $\mu$ -bromobis(tri-*tert*-butylphosphino)dipalladium(I) ([P(t-Bu)\_3PdBr]\_), tris(dibenzylideneacetone)dipalladium (Pd(dba)<sub>2</sub>), and bis(cyclopentadienyl)zirconium(IV) chloride hydride (Schwartz's reagent) were purchased from Strem Chemicals. Tri-tertbutylphosphine and methyl trimethyl dimethylketene acetal was purchased from Sigma-Aldrich. The following reagents were distilled prior to use: chlorotrimethylsilane (TMSCI), tertbutyldimethylsilyl trifluoromethanesulfonate (TBSOTf), and tetramethylethylenediamine (TMEDA); 1,2-dibromoethane was passed over basic Brockman Grade I 58 Å activated alumina and then stirred over 4 Å molecular sieves for 7 h before distillation. Diethylamine (Et<sub>2</sub>NH) was stirred over KOH for 1 h and then passed over basic Brockman Grade I 58 Å activated alumina prior to use. DBU was stirred over 4 Å molecular sieves for 3 h and then passed over basic Brockman Grade I 58 Å. N-pentane was dried over MgSO<sub>4</sub>. N-bromosuccinamide (NBS) was purified by recrystallization from deionized water. Reaction temperatures were controlled using an IKAmag temperature modulator, and unless stated otherwise, reactions were performed at room temperature (rt, approximately 23 °C). Melting points were determined using a MEL TEMP II melting point apparatus. Thin-layer chromatography (TLC) was conducted with EMD gel 60 F254 pre-coated plates (0.25 mm) and visualized using a combination of UV, anisaldehyde, iodine, vanillin, ninhydrin, and potassium permanganate staining. Silicycle Siliaflash P60 (particle size 0.040–0.063 mm) was used for flash column chromatography. <sup>1</sup>H NMR spectra were recorded on Bruker spectrometers (at 500 MHz or 600 MHz) and are reported relative to deuterated solvent signals. Data for <sup>1</sup>H NMR spectra are reported as follows: chemical shift ( $\delta$  ppm), multiplicity, coupling constant (Hz) and integration. <sup>13</sup>C NMR spectra were recorded on Bruker Spectrometers (at 125 or 150 MHz). Data for <sup>13</sup>C NMR spectra are reported in terms of chemical shift. IR spectra were recorded on a Perkin-Elmer 100 spectrometer and are reported in terms of frequency of absorption (cm<sup>-1</sup>). Optical rotations were measured with a Rudolf Autopol III Automatic Polarimeter. High-resolution mass spectra were obtained from the UC Irvine Mass Spectrometry Facility and the UCLA Molecular Instrumentation Center.

### **Experimental Procedures**

## A. Optimization of the total synthesis of indolactam V (1)



*N*-TIPS benzyloxyindole SI-2. To a flask containing NaH (60% dispersion in mineral oil, 0.700 g, 17.5 mmol, 1.3 equiv) at 0 °C was added a solution of 5-benzyloxyindole SI-1 (3.00 g, 13.5 mmol) in 1,2-dimethoxyethane (40 mL). The resulting solution was stirred at 0 °C for 20 min, then TIPSCl (4.34 mL, 20.3 mmol, 1.5 equiv) was added dropwise over 5 min. The resulting mixture was removed from the 0 °C bath and allowed to warm to 23 °C. After stirring for an additional 90 min, the reaction was quenched with H<sub>2</sub>O (2 mL). The biphasic mixture was concentrated under reduced pressure, then further diluted with Et<sub>2</sub>O (50 mL) and H<sub>2</sub>O (10 mL). The layers were separated, and then the aqueous layer was extracted with Et<sub>2</sub>O (2 × 50 mL). The combined organic layers were dried over MgSO<sub>4</sub>. Evaporation of the solvent under reduced pressure afforded the crude product, which was further purified by flash chromatography (3:1 Hexanes:CH<sub>2</sub>Cl<sub>2</sub>) to afford known SI-2<sup>1</sup> (4.82 g, 94% yield) as a white solid.



*N*-TIPS carbamate SI-4. Carbamate SI-4 was prepared following the general procedure described by Igarashi.<sup>2</sup> To a solution of *N*-TIPS benzyloxyindole (4.72 g, 12.4 mmol) in 1:1:1 *i*-PrOH:Hexanes:EtOAc (108 mL) was added 5% Pd/C (0.67 g, 0.32 mmol, 2.6 mol% Pd). The mixture was placed under an atmosphere of hydrogen (double-balloon), stirred for 2.5 h at 23 °C, and then filtered over celite (EtOAc eluent). Evaporation of the solvent under reduced pressure afforded crude SI-3 as a pink solid, which was used in the subsequent step without further purification.

To a solution of crude **SI-3** in CH<sub>2</sub>Cl<sub>2</sub> (60.0 mL) and Et<sub>3</sub>N (0.518 mL, 3.72 mmol, 0.3 equiv), was added *i*-PrNCO (3.64 mL, 37.2 mmol, 3 equiv. The solution was stirred at 23 °C for 24 h, then concentrated to dryness under reduced pressure. Purification by flash chromatography (2:1 Hexanes:Et<sub>2</sub>O) provided known *N*-TIPS carbamate **SI-4**<sup>1</sup> (4.48 g, 97% yield, 2 steps) as a white solid.



**N-TIPS silvlcarbamate SI-5.** Silvl carbamate SI-5 was prepared following the general procedure described by Hoppe and Snieckus for o-lithiation of isopropyl carbamates, with minor modifications.<sup>3,4</sup> To a solution of N-TIPS carbamate SI-4 (4.48 g, 11.98 mmol) and TMEDA (2.51 mL, 16.8 mmol, 1.4 equiv) in 3:1 Et<sub>2</sub>O:THF (120 mL) at 0 °C was added a solution of TBSOTf in *n*-pentane (1.30 M, 17.3 mL, 14.4 mmol, 1.2 equiv). After stirring for 5 min, the white suspension was allowed to warm to 23 °C over 30 min. TMEDA (6.28 mL, 41.9 mmol, 3.5 equiv) was added, and the mixture was cooled to -78 °C. A solution of *n*-BuLi in hexanes (1.43 M, 29.3 mL, 41.9 mmol, 3.5 equiv) was added dropwise over 55 min. The mixture was stirred at -78 °C for 3 h, then neat TMSCl (10.6 mL, 83.9 mmol, 7 equiv) was added dropwise over 1 h. The resulting mixture was stirred at -78 °C for 1 h, guenched with 1 M NaHSO<sub>4</sub> (50 mL), and allowed to warm to 23 °C over 45 min with vigorous stirring. The biphasic mixture was further diluted with Et<sub>2</sub>O (50 mL), the layers were separated, and then the aqueous layer was extracted with  $Et_2O$  (2 × 50 mL). The combined organic layers were dried over MgSO<sub>4</sub>. Evaporation of the solvent under reduced pressure afforded the crude product, which was further purified by flash chromatography (2:1 Hexanes:Et<sub>2</sub>O) to afford known silvlcarbamate SI-5<sup>1</sup> (5.33 g. quantitative yield) as a white solid.



6-Bromo silvlcarbamate SI-6. 6-Bromo silvlcarbamate SI-6 was prepared following the general procedure described by Snieckus for o-lithiation, with modifications.<sup>5</sup> To a solution of silylcarbamate SI-5 (2.19 g, 4.90 mmol) in 3:1 Et<sub>2</sub>O:THF (69.6 mL) at -78 °C was added TMEDA (1.02 mL, 6.86 mmol, 1.4 equiv), followed by a solution of TMSOTf in *n*-pentane (1.30 M, 3.91 mL, 5.90 mmol, 1.2 equiv). After stirring for 5 min, the white suspension was allowed to warm to 23 °C over 28 min, by which time TMEDA·TfOH had formed as an oil on the bottom of the flask. The mixture was placed in a hexanes and liquid nitrogen bath at -100 °C and TMEDA (2.56 mL, 17.2 mmol, 3.5 equiv) was added. A solution of sec-BuLi in cyclohexane (1.18 M, 37.4 mL, 44.1 mmol, 9 equiv) was added dropwise over 1.2 h. The mixture was stirred at -100 °C for 4.5 h, then neat 1,2-dibromoethane (5.09 mL, 58.8 mmol, 12.0 equiv) was added dropwise over 10 min. The resulting mixture was stirred at -100 °C for 3 h, guenched with 0.5 M aqueous NaHSO<sub>4</sub> (50 mL), and warmed to 23 °C over 40 min with vigorous stirring. The layers were separated, and the organic layer was washed successively with 1 M aqueous NaHSO<sub>4</sub> (50 mL) and brine (50 mL), then dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was purified by flash chromatography (5:1 Benzene:CH<sub>2</sub>Cl<sub>2</sub>) to afford known 6-bromo silylcarbamate SI- $6^6$  (2.12 g, 82% yield) as a white solid.



*N*-TIPS 6-bromo silyltriflate SI-7. To a solution of 6-bromo silylcarbamate SI-6 (0.636 g, 1.21 mmol) in MeCN (24 mL) were added DBU (0.427 mL, 3.03 mmol, 2.5 equiv) and Et<sub>2</sub>NH (0.187  $\mu$ L, 1.82 mmol, 1.5 equiv). The resulting mixture was placed in a heating bath maintained at 40 °C for 15 min, then allowed to cool to 23 °C. Next, a solution of PhNTf<sub>2</sub> (0.650 g, 1.82 mmol, 1.5 equiv) in MeCN (2.1 mL) was added. After stirring for 25 min, the reaction mixture was

passed over a plug of silica gel (EtOAc eluent). Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (30:1 Hexanes:Et<sub>2</sub>O) to provide known *N*-TIPS 6-bromo silyltriflate **SI-7**<sup>6</sup> (0.654 g, 95% yield) as a white solid.



*N*-H 6-bromo silyltriflate 9. To a solution of *N*-TIPS 6-bromo silyltriflate SI-7 (0.143 g, 0.250 mmol) in THF (9.4 mL) at -78 °C was added a solution of TBAF in THF (1.0 M, 250 µL, 0.250 mmol, 1 equiv) dropwise over 3 min. The solution was stirred for 15 min, then quenched with H<sub>2</sub>O (12 mL). The biphasic mixture was further diluted with EtOAc (12 mL). The layers were separated, and then the aqueous layer was extracted with EtOAc (2 × 12 mL). The combined organic layers were dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (2.5:1 Hexanes:CH<sub>2</sub>Cl<sub>2</sub>) to provide known bromo silyltriflate 9<sup>6</sup> (90.9 mg, 87% yield) as a white solid.



**Indolyne adduct 11.** To a stirred solution of *N*-H 6-bromo silyltriflate **9** (52.1 mg, 0.125 mmol) and peptide  $10^6$  (87.1 mg, 0.375 mmol, 3 equiv) in MeCN (1.25 mL) was placed in a 0 °C bath and added CsF (38.0 mg, 0.250 mmol, 2 equiv). The reaction mixture was stirred at 0 °C for 12 h, and was then allowed to warm to 23 °C. After stirring for an additional 12 h, the reaction mixture was filtered over silica gel (EtOAc eluent). Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (1:0.7:0.7 Hexanes:CH<sub>2</sub>Cl<sub>2</sub>:Et<sub>2</sub>O) to provide known indolyne adduct  $11^6$  (40.0 mg, 75% yield) as a clear oil.



Unsaturated ester 7. Indolyne adduct 11 was converted to SI-8 in 84% yield using our previously reported two-step procedure.<sup>6</sup> To a solution of SI-8 (98.2 mg, 0.252 mmol) in DMF (2.5 mL) was added K<sub>2</sub>CO<sub>3</sub> (69.7 mg, 0.504 mmol, 2 equiv). The resulting mixture was placed in a heating bath maintained at 65 °C for 10 h, then allowed to cool to 23 °C. The reaction mixture was passed over a plug of cotton (EtOAc eluent). Evaporation at 60 °C under reduced pressure afforded the crude product, which was further purified by flash chromatography (5:1 Hexanes:EtOAc) to provide known ester 7<sup>6</sup> (79.7 mg, 96% yield) as a white solid.



**Tricycle 12.** A modification of Piersanti's procedure for alkylation of indoles was employed to construct the desired 9-membered ring.<sup>7</sup> Inside a glove box,  $ZrCl_4$  (336.5 mg, 1.45 mmol, 15 equiv) and then  $CH_2Cl_2$  (0.96 mL) were added to a vial containing 7 (31.7 mg, 0.096 mmol). The reaction vessel was placed into an aluminum block maintained at 34 °C. After 16 h, the vial was transferred out of the glove box and the reaction mixture was added dropwise to saturated aqueous NaHCO<sub>3</sub> (15 mL) at 0 °C. The resulting solids were removed by filtration over celite (EtOAc eluent). The layers were separated and the aqueous layer was extracted with EtOAc (15 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (5:1  $\rightarrow$  2:1 Hexanes:EtOAc) to afford known tricycle 12<sup>6</sup> (28.5 mg, 90% yield) as a white solid.



Ester 13. Tricycle 12 was epimerized following the protocol described by Nakatsuka, with modifications.<sup>8</sup> To a solution of 12 (42.1 mg, 0.128 mmol) in MeOH (8.5 mL) was added NaHCO<sub>3</sub> (294.4 mg, 3.5 mmol, 27.4 equiv). The resulting mixture was placed in a heating bath maintained at 40 °C for 3 d, then allowed to cool to 23 °C. The reaction mixture was concentrated and diluted with EtOAc (50 mL) and H<sub>2</sub>O (50 mL). The organic layer was separated, and then the organic layer was washed with brine (50 mL), and dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude mixture, which was purified by flash chromatography (95:5  $\rightarrow$  90:10 Benzene:CH<sub>3</sub>CN) to afford known ester 13<sup>8</sup> (21.0 mg, 50% yield) and recovered epimer 12<sup>8</sup> (19.0 mg, 45% yield) as a white solid.



**Indolactam V (1).** Ester **13** was reduced following the protocol described by Nakatsuka, with modifications.<sup>8</sup> Inside a glove box, a vial was charged with **13** (125.4 mg, 0.381 mmol), LiBH<sub>4</sub> (54.8 mg, 2.515 mmol, 6.6 equiv) and THF (0.381 mL). The vial was removed from the glove box and allowed to stir for 2 h at 23 °C. After 2 h, the reaction mixture was poured into ice water (5 mL). The mixture was then extracted with  $CH_2Cl_2$  (50 mL). The organic layers were combined, washed with brine (15 mL), and dried over MgSO<sub>4</sub>. Evaporation of the solvent under reduced pressure afforded crude indolactam V (1), which was used in the subsequent step without further purification. Spectral data match those previously reported.<sup>8</sup>



Silylether 14. Indolactam V (1) was silvl protected following the protocol described by Kishi.<sup>9</sup> To a stirred solution of indolactam V (1) (41.7 mg, 0.317 mmol) in DMF (1.4 mL) was added TBSCI (20.6 mg, 0.137 mmol, 1.0 equiv), imidazole (46.5 mg, 0.684 mmol, 5.0 equiv), and TBAI (5.0 mg, 0.014 mmol, 0.1 equiv). The resulting mixture was allowed to stir at 23 °C. After 12 h, the reaction was guenched with saturated aqueous  $NH_4Cl$  (5 mL) and diluted with EtOAc (10 mL). The organic layer was separated, and then the organic layer was washed with brine (50 mL), and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was purified by flash chromatography (4:1 Hexane:EtOAc) to afford known silvlether 14 (118.5 mg, 90% yield over two steps) as a white solid. Silvlether 14: Mp = 192-195 °C;  $R_f 0.65$ (1:1 Hexanes:EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.05 (br s, 1H), 7.08 (t, J = 7.9, 1H), 6.91 (d, J = 8.0, 1H), 6.89 (s, 1H), 6.52 (d, J = 7.7, 1H), 6.19 (br s, 1H), 4.38 (d, J = 10.2, 1H), 4.24(d, J = 3.9, 1H), 3.65 (dd, J = 10.1, 4.3, 1H), 3.48 (t, J = 9.5, 1H), 3.17 (d, J = 17.4, 1H), 2.95-2.88 (m, 4H), 2.65–2.61 (m, 1H), 0.94 (d, J = 6.4, 3H), 0.91 (s, 3H), 0.89 (s, 9H), 0.64 (d, J = 6.7, 3H), 0.06 (s, 3H) 0.04 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 173.1, 148.0, 139.5, 123.0, 121.4, 118.1, 114.7, 106.4, 104.0, 71.3, 65.5, 55.2, 34.2, 33.0, 28.7, 26.0, 21.7, 19.6, 18.4, -5.2, -5.3; IR (film): 3320, 2928, 1643, 1251 cm<sup>-1</sup>; HRMS-ESI (m/z) [M + Na]<sup>+</sup> calculated for  $C_{23}H_{37}N_3O_2SiNa$ , 438.2553; found, 438.2554;  $[\alpha]^{20}_D - 124.00^{\circ}$  (c 0.10 CH<sub>2</sub>Cl<sub>2</sub>).

**B.** Cross-coupling to introduce the C7 sp<sup>2</sup>–sp<sup>3</sup> linkage



Ester 16b. Ester 16b was prepared following the general coupling protocol described by Hartwig for the cross-coupling of silvl ketene acetals with aryl bromides, with modifications.<sup>10</sup> A flamedried vial under N<sub>2</sub>, containing 7-bromoskatol  $(15)^{11}$  (9.9 mg, 0.047 mmol), was transferred to a glovebox. A magnetic stir bar was added, followed by P(tBu)<sub>3</sub> (4.7 µl, 4.7 µmol, 0.1 equiv),  $ZnF_2$  (2.5 mg, 0.025 mmol, 0.5 equiv), and a solution of Pd(dba)<sub>2</sub> (1.4 mg, 2.4  $\mu$ mol, 0.05 equiv) in DMF (0.47 mL). Trimethylsilyldimethylketene (21) (14.4 µl, 0.071 mmol, 1.5 equiv) was added and the vial was sealed with a teflon-coated cap and removed from the glovebox. The reaction was stirred at 80 °C for 12 h, cooled to 23 °C, and then filtered over silica (100% EtOAc eluent) and concentrated in vacuo. The crude residue was purified by preparative thin layer chromatography (3:1:1 Hexanes:CH<sub>2</sub>Cl<sub>2</sub>:EtO<sub>2</sub>) to afford ester 16b (9.9 mg, 91%) as an amorphous tan solid. Ester 16b: Rf 0.6 (3:1:1 Hexanes:CH<sub>2</sub>Cl<sub>2</sub>: EtO<sub>2</sub>); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.63 (br s, 1H), 7.52 (ddd, J = 7.8, 1.0, 1.0, 1H), 7.19 (dd, J = 7.5, 1.0 1H), 7.12 (dd, J= 7.8, 7.5 1H), 6.96 (ddd, J = 1.0, 1.0, 1.0, 1H), 3.61 (s, 3H), 2.32 (d, J = 1.0, 3H), 1.71 (s, 6H), <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 178.7, 134.1, 129.2, 126.5, 121.9, 119.2, 118.4, 117.9, 111.4, 52.8, 45.3, 25.2, 9.8; IR (film): 3428, 2950, 1713, 1434, 1264, 1152 cm<sup>-1</sup>; HRMS-ESI (*m/z*) [M + H]<sup>+</sup> calculated for C<sub>14</sub>H<sub>18</sub>NO<sub>2</sub>, 232.1332; found, 232.1328.



**Morpholine amide 16c.** Amide **16c** was prepared following the general protocol for the crosscoupling of α-bromoamides with aryl bromides described by Hartwig, with modifications.<sup>12</sup> Inside a glove box, a vial was charged with morpholine amide **SI-9** (390.0 mg, 1.65 mmol, 5 equiv), activated zinc dust (112.0 mg, 1.71 mmol, 5.2 equiv) and THF (1.4 mL). The vial was sealed and placed into a heating block maintained at 40 °C for 4 h. This heterogeneous solution was removed from the heat and immediately added to a solution of 7-bromoskatol **15**<sup>11</sup> (69.0 mg, 0.33 mmol) and [P(*t*-Bu)<sub>3</sub>PdBr]<sub>2</sub> (38.3 mg, 0.05 mmol, 0.15 equiv) in toluene (3.2 mL). The resulting solution was stirred at 80 °C for 12 h. After cooling to 23 °C, the reaction mixture was loaded directly onto a silica gel column and separated by flash chromatography (5:1 Hexane:EtOAc) to afford morpholine amide **16c** (50.3 mg, 53% yield) as a clear oil. Morpholine Amide **16c**: *R*<sub>f</sub> 0.08 (5:1 Hexanes:EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.35 (br s, 1H), 7.51– 7.46 (m, 1H), 7.12–7.08 (m, 2H), 6.95–6.93 (m, 1H), 3.89–2.45 (br m, 8H), 2.32 (d, *J* = 1.1, 3H), 1.67 (s, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 176.2, 133.7, 129.3, 128.1, 121.9, 119.6, 118.0, 116.1, 111.6, 67.1, 65.8, 47.5, 45.3, 43.7, 9.8; IR (film): 3365, 2920, 1619, 1426, 1245, 1112 cm<sup>-1</sup>; HRMS-ESI (*m/z*) [M - H]<sup>-</sup> calculated for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>, 285.1609; found, 285.1610.



## C. Total synthesis of (-)-pendolmycin (2)

Bromoindole 24. Silvlether 14 was functionalized following the general protocol described by Kishi, with modification.<sup>13</sup> To a stirred solution of silvlether **14** (9.5 mg, 0.023 mmol) in THF (2.3 mL) at -78 °C was added N-bromosuccinimide (4.1 mg, 0.023 mmol, 1.0 equiv) in THF (2.3 mL). After 10 min, the reaction warmed to -15 °C and stirred for an additional 10 min. The reaction was quenched with water (1 mL), diluted with EtOAc (10 mL) and then washed sequentially with water (10 mL), and brine (5 mL). The organic layers were combined and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was purified by flash chromatography (3:1 Hexane:EtOAc) to afford bromoindole 24 (6.8 mg, 87% yield) as a white solid. Bromoindole 24: Mp: 188–190 °C;  $R_f 0.6$  (2:1 Hexanes:EtOAc); <sup>1</sup>H NMR  $(500 \text{ MHz}, \text{CDCl}_3)$ :  $\delta$  8.20 (br s, 1H), 7.18 (d, J = 8.3, 1H), 6.94 (t, J = 1.8, 1H), 6.41 (d, J = 8.3, 1H), 6.16 (s, 1H), 4.30 (d, J = 10.2, 1H), 4.18–4.14 (m, 1H), 3.65 (dd, J = 10.2, 4.4, 1H), 3.48 (dd, J = 10.0, 9.1 1H), 3.17 - 3.10 (m, 1H), 2.93 - 2.87 (m, 4H), 2.66 - 2.55 (m, 1H) 0.93 (d, J = 6.3, 3.10 (m, 1H))3H), 0.90–0.88 (m, 9H), 0.62 (d, J = 6.8, 3H), 0.04 (d, J = 11.9, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 172.7, 147.6, 137.3, 125.1, 121.8, 119.1, 116.1, 107.6, 95.9, 71.5, 65.4, 55.0, 34.1, 33.0, 28.7, 26.0, 21.7, 19.7, 18.4, -5.2, -5.3; IR (film): 3369, 3325, 2928, 2857, 1647, 1502, 1251, 1104 cm<sup>-1</sup>; HRMS-ESI (m/z) [M + Na]<sup>+</sup> calculated for C<sub>23</sub>H<sub>36</sub>BrN<sub>3</sub>O<sub>2</sub>SiNa, 516.1658; found, 516.1659;  $[\alpha]^{20}$  -384.00° (c 0.10 CH<sub>2</sub>Cl<sub>2</sub>).



Morpholine amide 25. Amide 25 was prepared following the general protocol described by Hartwig for the cross-coupling of  $\alpha$ -bromoamides with aryl bromides, with modifications.<sup>12</sup> Inside a glove box, a vial was charged with morpholine amide SI-9 (19.1 mg, 0.081 mmol, 10.0 equiv), activated zinc dust (5.5 mg, 0.084 mmol, 10.4 equiv) and THF (0.3 mL). The vial was sealed and placed into a heating block maintained at 40 °C for 4 h. This heterogeneous solution was removed from the heat and immediately added to a solution of bromoindole 24 (4.0 mg, 8 µmol) and [P(t-Bu)<sub>3</sub>PdBr]<sub>2</sub> (0.9 mg, 1 µmol, 15 mol%) in toluene (0.2 mL). The resulting solution was stirred at 80 °C for 12 h. After cooling to 23 °C, the reaction mixture was loaded directly onto a silica gel column and separated by flash chromatography (1:1 Hexane:EtOAc) to afford morpholine amide 25 (2.8 mg, 61% yield) as a light yellow oil. Morpholine amide 25:  $R_{\rm f}$ 0.4 (1:1 Hexanes: EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.52 (br s, 1H), 6.96 (d, J = 8.0, 1H), 6.86 (s, 1H), 6.49 (d, J = 8.0, 1H), 6.16 (br s, 1H), 4.33 (d, J = 10.0, 1H), 4.25–4.16 (m, 1H), 3.70-3.56 (m, 4H), 3.47 (t, J = 10.0, 1H), 3.39-3.20 (m, 3H), 3.14 (d, J = 17.4, 3H), 2.66-2.55(m, 1H), 1.70 (s, 3H), 1.42 (s, 3H), 1.10 (d, J = 6.6, 3H), 0.93 (d, J = 6.6, 4H), 0.88 (s, 9H), 0.55 (d, J = 6.6, 3H), 0.05 (d, J = 12.5, 6H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  176.6, 172.9, 170.9, 147.0, 136.7, 122.0, 120.5, 118.7, 117.2, 114.3, 106.3, 71.2, 65.5, 56.7, 55.0, 44.8, 36.4, 34.1, 32.9, 28.7, 26.0, 23.4, 21.7, 20.7, 19.7, 18.4 -5.2, -5.3; IR (film): 3375, 2956, 2928, 2857, 1665, 1620, 1508 cm<sup>-1</sup>; HRMS-ESI (m/z) [M + Na]<sup>+</sup> calculated for C<sub>31</sub>H<sub>50</sub>N<sub>4</sub>O<sub>4</sub>SiNa, 593.3498; found, 593.3499;  $[\alpha]^{22}_{D}$  317.80° (c 0.10 CH<sub>2</sub>Cl<sub>2</sub>).



**Olefin 27.** Aldehyde **26** was prepared following the general protocol described by Georg for the reduction of tertiary amides, with modifications.<sup>14</sup> Inside a glove box, Cp<sub>2</sub>ZrHCl (33.9 mg, 0.131 mmol, 5 equiv) and THF (0.7 mL) were added to a vial containing **25** (15.0 mg, 0.026 mmol). The reaction vessel was placed in an aluminum block maintained at 60 °C. After stirring for 2 h, the vial was transferred out of the glove box and the reaction mixture was quenched with H<sub>2</sub>O (5 mL) and EtOAc (5 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with brine (15 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was used in the subsequent step without further purification. Aldehyde **26**:  $R_f$  0.8 (1:1 Hexanes:EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  9.33 (s, 1H), 8.39 (br s, 1H), 7.07 (d, *J* = 8.2, 1H), 6.85 (s, 1H), 6.56 (d, *J* = 8.2, 1H), 6.15 (s, 1H), 4.33 (d, *J* = 10.1, 1H), 4.21–4.12 (m, 1H), 3.62 (dd, *J* = 10.1, 4.2, 1H), 3.45 (t, *J* = 10.1, 1H), 3.17–3.10 (m, 1H), 2.92 (s, 3H), 2.90–2.86 (m, 1H), 2.66–2.57 (m, 1H) 1.56 (s, 3H), 0.93 (d, *J* = 6.3, 3H), 0.87 (s, 9H), 0.62 (d, *J* = 6.7, 3H), 0.09–0.0 (m, 9H).

To a solution of methyl triphenylphosphonium bromide (48.8 mg, 0.137 mmol, 12 equiv) in THF (0.29 mL) at 0 °C was added potassium *tert*-butoxide (15.3 mg, 0.137 mmol, 12 equiv). The resulting mixture was stirred at 0 °C for 30 min then warmed 23 °C. After 30 min the vial was cooled to 0 °C and a solution of aldehyde **26** (5.5 mg, 0.011 mmol) in THF (0.29 mL) was added. After 1 h, the reaction was warmed to 23 °C for 2 h. The reaction is quenched with water (5 mL) and diluted with EtOAc (10 mL). The layers were separated, and then the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (5 mL) and dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (4:1 Hexanes:EtOAc + 2% Et<sub>3</sub>N) to provide olefin **27** (2.9 mg, 52% yield) as a light yellow oil. Olefin **27**:  $R_f$  0.3 (5:1 Hexanes:EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): 8.47 (br s, 1H), 7.01 (d, *J* = 8.0, 1H), 6.85–6.79 (m, 1H), 6.53–6.46 (m,

1H), 6.24–6.10 (m, 2H), 5.33 (dd, J = 17.8, 1.2, 1H), 5.22 (dd, J = 10.5, 1.2 1H), 4.32 (d, J = 10.5, 1H) 4.29–4.21 (m, 1H) 3.63 (dd, J = 10.5, 4.2, 1H), 3.49–3.41 (m, 1H), 3.15 (app d, J = 17.8, 1H), 2.91 (s, 3H), 2.89–2.72 (m, 1H), 2.68–2.57 (m, 1H), 1.51 (s, 3H), 1.48 (s, 3H), 0.95–0.90 (m, 3H), 0.87 (s, 9H), 0.65 (d, J = 6.5, 3H), 0.05 (s, 3H), 0.02 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  173.2, 149.8, 146.8, 137.6, 122.8, 121.2, 119.2, 118.8, 114.3, 111.4, 106.5, 71.3, 65.5, 55.1, 40.3, 34.1, 33.1, 28.7, 27.4, 26.9, 26.0, 21.7, 19.7, 18.4, -5.2, -5.3; IR (film): 3452, 3380, 2956, 2929, 2858, 1656, 1507 cm<sup>-1</sup>; HRMS-ESI (m/z) [M + Na]<sup>+</sup> calculated for C<sub>28</sub>H<sub>45</sub>N<sub>3</sub>O<sub>2</sub>SiNa, 506.3179; found, 506.3182; [ $\alpha$ ]<sup>20</sup><sub>D</sub> –126.00° (c 0.10 CH<sub>2</sub>Cl<sub>2</sub>).



**Pendolmycin (2).** To a solution of olefin **27** (6.7 mg, 0.014 mmol) in THF (0.276 mL) at 0 °C was added a solution of TBAF in THF (1.0 M, 138  $\mu$ L, 0.138 mmol, 10 equiv) dropwise over 3 min. The solution was stirred for 15 min, and then quenched with H<sub>2</sub>O (2 mL). The biphasic mixture was further diluted with EtOAc (10 mL) and H<sub>2</sub>O (5 mL). The layers were separated, and then the aqueous layer was extracted with EtOAc (3 × 15 mL). The combined organic layers were dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (5:1 CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH) to provide pendolmycin (**2**) (3.6 mg, 70% yield) as a viscous oil. Spectral data for synthetic **2** was consistent with literature reports.<sup>15</sup> Pendolmycin (**2**): R<sub>f</sub> 0.2 (5:1 CH<sub>2</sub>Cl<sub>2</sub>:CH<sub>3</sub>OH); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): Major conformer:  $\delta$  8.48 (br s, 1H), 7.01 (d, *J* = 8.0, 1H), 6.86–6.82 (m, 1H), 6.48 (d, *J* = 8.0, 1H), 6.19 (dd, *J* = 17.8, 10.5, 1H), 5.32 (dd, *J* = 17.8, 1.4, 1H), 5.21 (dd, *J* = 10.5, 1.0, 1H), 4.34 (d, *J* = 10.0, 1H), 4.36–4.29 (m, 1H), 3.74 (app d, *J* = 12.0, 1H), 3.62–3.39 (m, 2H), 3.39–3.32 (m, 1H), 3.17 (app d, *J* = 17.0, 1H), 3.08 (dd, *J* = 17.0, 4.0, 1H), 2.9 (s, 3H), 2.65–2.55 (m, 1H) 1.51 (s, 3H), 1.48 (s, 3H), 0.92 (d, *J* = 7.0, 3H), 0.64 (d, *J* = 7.0, 3H); Minor conformer [26/31 protons were discernable];  $\delta$  8.72 (br s, 1H), 7.12 (d, *J* = 7.8, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.12 (d, *J* = 7.8, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.12 (d, *J* = 7.8, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d, *J* = 2.0, 1H), 7.12 (d, *J* = 7.8, 1H), 7.02 (d, *J* = 7.8, 1H), 6.97 (d

1H), 6.21 (dd, 17.8, 10.5, 1H), 5.37 (dd, *J*=17.8, 1.4, 1H), 5.27 (dd, *J*=10.5, 1.4, 1H), 4.48–4.39 (m, 1H), 3.43 (app d, *J*=7.2, 1H), 3.44–3.39 (dd, *J*=1.8, 1.4, 1H), 2.99 (d, *J*=10.5, 1.4, 1H), 2.80 (dd, *J*=15.0, 2.0, 1H), 2.73 (s, 3H), 2.44–2.31 (m, 1H), 1.53 (s, 3H), 1.52 (s, 3H), 1.25 (d, *J*=6.7, 1H), 0.94 (d, *J*=6.7, 3H).

#### D. Total syntheses of (-)-lyngbyatoxin A (3) and (-)-teleocidin A-2 (4)



**Bromo ester SI-10.** α-Bromo methyl ester **SI-10** was prepared following the known protocol described by Webber for the  $\alpha$ -bromination of esters, with modifications.<sup>16</sup> A flask containing THF (33.4 mL) and diisopropylamine (2.81 mL, 20.03 mmol, 2.4 equiv) was cooled to -78 °C and then a solution of *n*-BuLi (8.8 mL, 2.55 M in hexanes, 2.7 equiv) was added dropwise over 5 min. The reaction was stirred for an additional 10 min at -78 °C and then warmed to 23 °C over 1 h. The mixture was cooled to -78 °C and TMSCI (2.8 mL, 21.8 mmol, 2.61 equiv) was added dropwise over 5 min. To the resulting clear solution was added ester 28 (1.42 g, 8.35 mmol) as a solution in THF (41.7 mL) over 10 min. The resulting yellow solution was stirred at -78 °C for 20 min and N-bromosuccinamide (3.86 g, 21.7 mmol, 2.6 equiv) was added quickly under a stream of nitrogen. The flask was purged with nitrogen for 1 min and allowed to warm to 23 °C in the absence of light over 2.5 h. The reaction was guenched with saturated agueous NH<sub>4</sub>Cl (30 mL) and further diluted with water (200 mL) and Et<sub>2</sub>O (200 mL). The layers were separated and the aqueous layer was extracted with  $Et_2O$  (3 × 200 mL). The organics were combined, washed with brine (50 mL), and dried over MgSO<sub>4</sub>. Evaporation under reduced pressure provided a crude light vellow oil, which was purified by flash chromatography (60:1 Hexane:Et<sub>2</sub>O) to afford bromo ester SI-10 (2.03 g, 98% yield) as a yellow oil. Bromo ester SI-10: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  5.12–5.06 (m, 1H), 3.78 (s, 3H), 2.18–1.96 (m, 4H), 1.91 (s, 3H), 1.68 (s, 3H), 1.61 (s, 3H).



**a-Bromo amide 29.** Carboxylic acid **SI-11** was prepared following the general protocol by Xia for the saponification of methyl esters, with modifications.<sup>17</sup> To a stirred solution of  $\alpha$ -bromo methyl ester **SI-10** (12.50 g, 50.1 mmol) in THF (157 mL) at -15 °C was added a solution of lithium hydroxide monohydrate (3.13 g, 74.6 mmol, 1.4 equiv) in H<sub>2</sub>O (133 mL) dropwise via syringe pump. After 7 h, the reaction was quenched with 1 M HCl (100 mL) and then diluted with EtOAc (100 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (3 × 100 mL). The combined organic layers were dried over MgSO<sub>4</sub>. Evaporation of the solvent under reduced pressure afforded crude **SI-11**, which was used in the subsequent step without further purification.

Amide **29** was prepared from crude **SI-11** following a general protocol for the coupling of esters to amines using 1,1'-carbonyldiimidazole, with modifications.<sup>18</sup> To a solution of crude **SI-11** in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) was added 1,1'-carbonyldiimidazole (12.99 g, 80.16 mmol, 1.6 equiv). After stirring for 15 min, morpholine (10.83 mL, 125.25 mmol, 2.5 equiv) was added and the reaction was allowed to stir for 6 h. The reaction was quenched with 5% citric acid (400 mL), concentrated in vacuo, and then diluted with H<sub>2</sub>O (150 mL) and Et<sub>2</sub>O (150 mL). The organic layer was separated, washed with brine (50 mL), and then dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was purified by flash chromatography (5:1 Hexanes:EtOAc) to afford  $\alpha$ -bromo amide **29** (11.0 g, 72% yield, over two steps) as a yellow oil.  $\alpha$ -Bromo amide **29**:  $R_f$  0.7 (1:1 Hexanes:EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  5.11–5.05 (m, 1H), 4.00–3.66 (m, 8H), 2.30–1.90 (m, 7H), 1.68 (s, 3H), 1.61 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  168.6, 133.1, 122.3, 66.6, 61.4, 43.0, 30.5, 25.7, 24.7, 17.7; IR (neat): 2967, 2916, 2855, 1635, 1418 cm<sup>-1</sup>; HRMS-ESI (*m/z*) [M + H]<sup>+</sup> calculated for C<sub>13</sub>H<sub>22</sub>BrNO<sub>2</sub>, 304.0907; found, 304.0901.



Morpholine amides 31 and 32. Amides 31 and 32 were prepared following the general protocol described by Hartwig for the cross-coupling of a-bromoamides with aryl bromides, with modifications.<sup>12</sup> Inside a glove box, a vial was charged with a magnetic stir bar,  $\alpha$ -bromo amide 29 (41.2 mg, 0.135 mmol, 10 equiv), activated zinc dust (8.8 mg, 0.134 mmol, 9.9 equiv), and THF (0.32 mL). The vial was sealed and placed into a heating block maintained at 50 °C for 12 h. This clear, pale yellow solution was removed from the heat and immediately added to a solution of bromoindole 24 (6.7 mg, 0.0135 mmol), LiBr (1.2 mg, 0.0135 mmol, 1.0 equiv) and [P(t-Bu)<sub>3</sub>PdBr]<sub>2</sub> (1.6 mg, 2 µmol, 15 mmol%) in toluene (0.2 mL). The resulting solution was stirred at 80 °C for 12 h. The reaction mixture was passed through a silica gel plug (EtOAc eluent) and concentrated in vacuo. The crude residue was separated by preparatory thin layer chromatography (2:1 Hexane:EtOAc) to afford two separate diastereomeric amides 31 (1.8 mg, 43% yield) and 32 (2.4 mg, 32% yield) as light yellow viscous oils. Morpholine amide 31:  $R_{\rm f}$  0.7 (2:1 Hexanes: EtOAc): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.52 (br s. 1H), 6.89 (d. J = 8.2, 1H), 6.82 (br s, 1H), 6.46 (d, J = 8.2, 1H), 6.13 (br s, 1H), 4.40–4.00 (m, 1H), 4.31 (d, J = 10.2, 1H), 4.28– 4.20 (m, 1H), 3.65 (dd, J = 10.2, 4.3, 2H), 3.48 (t, J = 9.9, 1H), 3.39–2.70 (m, 14H), 2.69–2.50 (m, 1H), 2.45–1.66 (m, 10H), 0.94–0.91 (m, 4H), 0.88 (s, 9H), 0.54 (br s, 3H), 0.04 (s, 3H), 0.02 (s. 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>); δ 172.9, 146.9, 136.8, 124.5, 121.8, 118.7, 114.1, 106.2, 71.3, 67.2, 65.9, 65.6, 61.6, 55.1, 54.5, 47.5, 46.0, 43.7, 38.8, 34.1, 32.9, 29.9, 28.7, 26.0, 25.8, 23.2, 21.7, 20.3, 19.7, 17.6, -5.2, -5.3; IR (film): 3383, 2928, 1664, 1508, 1115 cm<sup>-1</sup>; HRMS-ESI (m/z) [M + H]<sup>+</sup> calculated for C<sub>36</sub>H<sub>59</sub>N<sub>4</sub>O<sub>4</sub>Si, 639.4305; found, 639.4301;  $[\alpha]^{22}_{D}$  -108.00 (c 0.10 CH<sub>2</sub>Cl<sub>2</sub>). Morpholine amide **32**:  $R_f$  0.7 (2:1 Hexanes:EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$ 8.53 (br s, 1H), 6.95 (d, J = 8.2, 1H), 6.84 (br s, 1H), 6.46 (d, J = 8.2, 1H), 6.14 (br s, 1H), 5.25– 5.00 (m, 1H), 4.32 (d, J = 10.0, 1H), 4.24–4.16 (br m, 1H), 3.70–3.42 (m, 1H) 3.64 (dd, J = 10.0, 1H) 4.1, 2H), 3.46 (t, J = 9.9, 1H), 3.40–3.0 (m, 6H), 2.90 (dd, J = 17.9, 4.1, 1H) 2.90 (s, 3H), 2.66–

2.51 (m, 1H), 2.35–1.81 (m, 5H), 1.79–1.58 (m, 8H), 0.96–0.89 (m, 4H), 0.87 (s, 9H), 0.52 (d, J = 6.6, 3H), 0.05 (s, 3H), 0.03 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) [28/36 carbons were discernable]:  $\delta$  175.5, 172.9, 171.3, 147.0, 136.6, 118.7, 114.2, 106.2, 71.2, 67.2, 65.9, 65.5, 60.6, 55.0, 47.5, 34.2, 32.9, 29.8, 29.4, 28.8, 26.0, 21.7, 21.2, 19.7, 18.4, 14.4, -5.2, -5.3; IR (film): 3375, 2928, 1666, 1508, 1115 cm<sup>-1</sup>; HRMS-ESI (*m*/*z*) [M – H]<sup>-</sup> calculated for C<sub>36</sub>H<sub>57</sub>N<sub>4</sub>O<sub>4</sub>Si, 637.4149; found, 637.4147; [ $\alpha$ ]<sup>22</sup><sub>D</sub>–106.00 (c 0.10 CH<sub>2</sub>Cl<sub>2</sub>).

*Note*: <sup>1</sup>H NMR and <sup>13</sup>C NMR integrations and peaks were complicated by the presence of major and minor conformers.<sup>19</sup> Empirical data is therefore reported for compounds **31–34**, **SI-12** and **SI-13**. Absolute stereochemical configuration for amides **31** and **32** were determined by subjecting each compound to the subsequent synthetic steps and matching each resulting compound to known spectral data for the natural products **3** and **4**.



**Olefin 34.** Aldehyde **33** was prepared following the general protocol described by Georg for the reduction of tertiary amides, with modifications.<sup>14</sup> Inside a glove box, Cp<sub>2</sub>ZrHCl (7.3 mg, 0.03 mmol, 10 equiv) and THF (0.3 mL) were added to a vial containing **31** (1.8 mg, 3 µmol). The reaction vessel was placed into an aluminum block maintained at 50 °C. After stirring for 12 h, the vial was transferred out of the glove box. The reaction mixture was quenched with silica gel (10.0 mg) and EtOAc with 2% Et<sub>3</sub>N (1.0 mL), and then stirred for 1 h. The mixture was eluted through a plug of silica gel (EtOAc with 2% Et<sub>3</sub>N eluent). Evaporation under reduced pressure afforded crude **33**, which was used in the subsequent step without further purification. Aldehyde **33**:  $R_f$  0.9 (1:1 Hexanes:EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  9.33 (s, 1H), 8.5 (br s, 1H), 7.05 (d, J = 8.2, 1H), 6.83 (b s, 1H), 6.55 (d, J = 8.2, 1H), 6.16 (s, 1H), 5.18–5.01 (m, 1H), 4.33 (d, J = 9.9, 1H), 4.26–4.08 (m, 1H), 3.78–3.68 (m, 1H), 3.63 (dd, J = 10.9, 4.8, 1H), 3.45 (t, J = 9.9,

1H), 3.11–3.06 (m, 1H), 2.91 (s, 3H), 2.79–2.49 (m, 2H), 2.43–1.76 (m, 5H), 1.65 (s, 2H), 1.63 (s, 2H), 1.42–1.40 (m, 1H), 0.94–0.88 (m, 9H), 0.86–0.80 (m, 3H), 0.82 (dd, *J* = 9.9, 6.7, 2H) 0.58 (d, *J* = 6.7, 3H), 0.05 (s, 3H), 0.02 (s, 3H).

A vial was charged with methyl triphenylphosphonium bromide (266.5 mg, 0.746 mmol, 265 equiv) and placed in a 0 °C bath. To this vial was added a solution of potassium tertbutoxide (79.0 mg, 0.704 mmol, 250 equiv) in THF (1.0 mL) dropwise over 2 min, and the resulting yellow mixture was allowed to warm to 23 °C over 30 min. After 1 h, an aliquot of the resulting ylide stock solution (20.0 µl, 5 equiv) was added dropwise to a solution of aldehyde 33 (3 µmol) in THF (0.3 mL) at 0 °C. After 1 h, the reaction was warmed up to 23 °C and stirred for 12 h. The reaction was guenched with water (1 mL) and EtOAc (1 mL). The layers were separated, and then the aqueous layer was extracted with EtOAc ( $3 \times 5$  mL). The combined organic layers were dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (1:199 Acetone:Benzene) to provide olefin 34 (1.0 mg, 64% yield over two steps) as a viscous light yellow oil. Olefin 34:  $R_{\rm f}$ 0.5 (5:1 Hexanes: EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.54–8.47 (m, 1H), 6.97 (d, J = 8.1, 1H), 6.80 (br s, 1H), 6.48 (d, J = 8.1, 1H), 6.17 (dd, J = 17.6, 10.6, 1H), 6.15 (br s, 1H), 5.36-5.23 (m, 3H), 5.13–5.03 (m, 1H), 4.31 (d, J = 10.0, 1H), 4.24 (dd, J = 10.0, 3.6, 1H), 3.63 (dd, J= 10.0, 3.6, 1H), 3.46 (t, J = 10.0, 1H), 3.13 (d, J = 17.6, 1H), 3.00–2.85 (s, 5H), 2.85–2.73 (m, 1H), 2.65–2.57 (m, 1H), 2.55–1.73 (m, 5H), 1.65 (app s, 2H), 1.49–1.44 (m, 6H), 0.88 (s, 9H), 0.64 (d, J = 6.8, 3H), 0.05 (s, 3H), 0.02 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  173.3, 148.6, 146.7, 137.7, 131.6, 124.8, 121.6, 121.0 120.1, 118.9, 114.2, 112.6, 106.5, 71.3, 65.5, 55.1, 43.4, 39.8, 38.7, 34.1, 33.0, 32.1, 28.7, 26.0, 24.2, 23.2, 21.7, 19.7, 18.4, 17.7, 14.3, -5.2, -5.3; IR (film): 2927, 2856, 1662, 1508, 1105 cm<sup>-1</sup>; HRMS-ESI (m/z) [M – H]<sup>-</sup> calculated for  $C_{33}H_{52}N_3O_2Si$ , 550.38233; found, 550.38368;  $[\alpha]^{20}D_-98.00$  (c 0.10 CH<sub>2</sub>Cl<sub>2</sub>).



Lyngbyatoxin A (3). Lyngbyatoxin A (3) was prepared following the general protocol for desilvlation described by Kishi, with modifications.<sup>9</sup> A vial was charged with lithium tetrafluoroborate (85.0 mg, 0.91 mmol, 500 equiv) and CH<sub>3</sub>CN (0.91 mL). An aliquot of the resulting mixture (1.0 M, 9 µL, 9 µmol, 5 equiv) was added dropwise to a solution of 34 (1.0 mg, 1.8 µmol) in THF (0.25 mL) over 1 min. After the solution was stirred for 20 min, (±)camphorsulfonic acid (2.1 mg, 9 µmol, 5 equiv) was added and the reaction was stirred for 24 h at 23 °C. The mixture was diluted with EtOAc (1 mL) and H<sub>2</sub>O (1 mL). The layers were separated, and then the aqueous layer was extracted with EtOAc ( $3 \times 5$  mL). The combined organic layers were dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (17:2:1 Hexanes:CHCl<sub>3</sub>:*i*PrOH) to provide lyngbyatoxin A (3) (0.5 mg, 63% yield) as a viscous light vellow oil. Lyngbyatoxin A (3): R<sub>f</sub> 0.6 (100% EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ (major conformer) 8.52 (br s, 1H), 6.97 (d, J = 8.2, 1H), 6.83-6.77 (m, 1H), 6.48 (d, J = 8.2, 1H), 6.34 (s, 1H), 6.18 (dd, J = 18.0, 1H)10.5, 1H), 5.32 (d, J = 18.0, 1H), 5.28 (d, J = 10.5, 1H), 5.12–5.02 (m, 1H), 4.30 (d, J = 10.0, 1H), 4.29-4.20 (m, 1H), 3.75 (dd, J = 10.7, 4.2 1H), 3.54-3.50 (m, 1H), 3.18 (br d, J = 17.0, 1H), 2.99 (dd, J = 15.0, 11.0, 1H), 2.91 (s, 3H), 2.58 (dqg, J = 10.7, 6.5, 6.5, 1H), 2.04–2.16 (m, 5H), 1.65 (s, 3H), 1.47 (s, 3H), 1.44 (s, 3H) 0.92 (d, J = 6.5, 3H), 0.64 (d, J = 6.5, 3H);  $\delta$  (minor conformer) [27/39 protons were discernable] 8.76 (br s, 1H), 7.10 (d, J = 8.0, 1H), 7.01 (d, J =8.0, 1H), 5.34 (d, J = 18.0, 1H), 4.46–4.40 (m, 1H), 3.46 (dd, J = 11.0, 6.7, 1H), 3.38 (dd, J = 10.0, 3H), 3.38 (dd, J = 10.0, 3H), 3H (dd, J = 10.0, 3H (dd, J = 10.0, 3H), 3H (dd, J = 10.0 11.0, 6.7, 1H), 2.80 (dd, J = 15.0, 1.5, 1H), 2.74 (s, 3H), 2.39 (dag, J = 10.8, 6.5, 6.5, 1H), 1.63 (s, 3H), 1.50 (s, 3H), 1.49 (s, 3H), 1.25 (d, J = 6.5, 3H), 0.97 (d, J = 6.5, 3H).



**Olefin SI-13.** Aldehyde **SI-12** was prepared following the general protocol described by Georg for the reduction of tertiary amides, with modifications.<sup>14</sup> Inside a glove box, Cp<sub>2</sub>ZrHCl (7.7 mg, 0.03 mmol, 10 equiv) and THF (0.3 mL) were added to a vial containing **32** (1.9 mg, 3 µmol). The reaction vessel was placed into an aluminum block maintained at 50 °C. After stirring for 12 h, the vial was transferred out of the glove box. The reaction mixture was quenched with silica gel (10.0 mg) and EtOAc with 2% Et<sub>3</sub>N (1.0 mL), and then stirred for 1 h. The mixture was eluted through a plug of silica gel (EtOAc with 2% Et<sub>3</sub>N eluent). Evaporation under reduced pressure afforded crude **SI-12**. *R*f 0.9 (1:1 Hexanes:EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  9.33 (s, 1H), 8.5 (br s, 1H), 7.04 (d, *J* = 8.4, 1H), 6.84 (m, 1H), 6.55 (d, *J* = 8.4, 1H), 6.16 (s, 1H), 5.15–4.98 (m, 1H), 4.47–3.97 (m, 2H), 4.43 (d, *J* = 10.0, 1H), 3.78–3.68 (m, 1H), 3.61 (dd, *J* = 10.0, 4.3, 2H), 3.44 (t, *J* = 10.0, 1H), 3.17–3.10 (m, 2H), 2.91 (s, 3H), 2.79–2.54 (m, 3H), 2.23–1.81 (m, 5H), 1.41 (s, 3H), 0.87 (m, 9H), 0.77 (dd, *J* = 10.0, 6.7, 3H) 0.57 (d, *J* = 6.7, 3H), 0.05 (s, 3H), 0.02 (s, 3H).

A vial was charged with methyl triphenylphosphonium bromide (117.0 mg, 0.328 mmol, 110 equiv) and placed in a 0 °C bath. To this vial was added a solution of potassium *tert*butoxide (33.3 mg, 0.297 mmol, 100 equiv) in THF (1.0 mL) dropwise over 2 min and the resulting yellow mixture was allowed to warm to 23 °C over 30 min. After 1 h, an aliquot of the resulting ylide stock solution (50.0  $\mu$ l, 5 equiv) was added dropwise to a solution of aldehyde **SI-12** (3  $\mu$ mol) in THF (0.3 mL) at 0 °C. After 1 h, the reaction was warmed up to 23 °C and stirred for 12 h. The reaction was quenched with water (1 mL) and EtOAc (1 mL). The layers were separated, and then the aqueous layer was extracted with EtOAc (3 × 5 mL). The combined organic layers were dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (1:199 Acetone:Benzene) to provide olefin **SI-13** (1.2 mg, 73% yield over two steps) as a viscous light yellow oil. Olefin **SI-13**:  $R_{\rm f}$  0.5 (5:1 Hexanes:EtOAc); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.54 (br m, 1H), 6.98 (d, J = 8.1, 1H), 6.82 (br s, 1H), 6.49 (d, J = 8.1, 1H), 6.21 (dd, J = 17.6, 10.6, 1H), 6.15 (br s, 1H), 5.32–5.22 (m, 2H), 5.13–5.01 (m, 1H), 4.31 (d, J = 10.1, 1H), 4.25 (m, 1H), 3.63 (dd, J = 10.1, 4.5, 1H), 3.45 (t, J = 10.1, 1H), 3.13 (d, J = 17.7, 1H), 2.91 (s, 3H), 2.88–2.74 (m, 2H), 2.66–2.54 (m, 1H), 2.10–1.70 (m, 3H), 1.65–1.61 (m, 2H), 1.45 (s, 2H), 1.43 (s, 1H), 1.38 (s, 2H), 0.88 (s, 9H), 0.85 (dd, J = 6.8, 4.5, 2H), 0.83–0.78 (m, 1H), 0.75 (dd, J = 4.5, 6.8, 2H), 0.60 (d, J = 6.8, 3H), 0.05 (s, 3H), 0.02 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  173.2, 149.3, 146.7, 137.6, 131.6, 124.7, 121.2, 120.4, 118.7, 114.1, 112.2, 106.0, 71.3, 65.5, 55.0, 43.5, 39.6, 38.1, 34.2, 32.9, 32.1, 28.7, 26.0, 24.9, 23.3, 22.7, 21.8, 19.6, 18.4, 17.5, 14.3, -5.2, -5.3; IR (film): 2927, 2854, 1662, 1466, 1105 cm<sup>-1</sup>; HRMS-ESI (m/z) [M – H]<sup>-</sup> calculated for C<sub>33</sub>H<sub>52</sub>N<sub>3</sub>O<sub>2</sub>Si, 550.38233; found, 550.38371; [ $\alpha$ ]<sup>20</sup><sub>D</sub> –136.00 (c 0.10 CH<sub>2</sub>Cl<sub>2</sub>).



**Teleocidin A-2 (4).** Teleocidin A-2 (4) was prepared following the general protocol for desilylation described by Kishi, with modifications.<sup>9</sup> A vial was charged with lithium tetrafluoroborate (63.7 mg, 0.68 mmol, 250 equiv) and CH<sub>3</sub>CN (0.68 mL). An aliquot of the resulting mixture (1.0 M, 14  $\mu$ L, 14  $\mu$ mol, 5 equiv) was added dropwise to a solution of **SI-13** (1.5 mg, 3  $\mu$ mol) in THF (0.25 mL) over 1 min. After the solution was stirred for 20 min, (±)-camphorsulfonic acid (3.2 mg, 14  $\mu$ mol, 5 equiv) was added and the reaction was stirred for 24 h at 23 °C. The mixture was diluted with EtOAc (1 mL) and H<sub>2</sub>O (1 mL). The layers were separated, and then the aqueous layer was extracted with EtOAc (3 × 5 mL). The combined organic layers were dried over MgSO<sub>4</sub>. Evaporation under reduced pressure afforded the crude product, which was further purified by flash chromatography (17:2:1 Hexanes:CHCl<sub>3</sub>:*i*PrOH) to provide teleocidin A-2 (4) (0.5 mg, 63% yield) as a viscous light yellow oil. Teleocidin A-2 (4):

 $R_f 0.6 (100\% EtOAc)$ ; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  (major conformer) 8.53 (br s, 1H), 6.98 (d, J = 8.1, 1H), 6.83–6.80 (m, 1H), 6.49 (d, J = 8.1, 1H), 6.20 (dd, J = 18.0, 10.5, 1H), 5.30 (d, J = 18.0, 1H), 5.26 (d, J = 10.5, 1H), 5.10–5.05 (m, 1H), 4.34 (d, J = 10.5, 1H), 4.37–4.30 (m, 1H), 3.72 (dd, J = 10.8, 4.0 1H), 3.54–3.44 (m, 1H), 3.18 (br d, J = 17.0, 1H), 2.96 (dd, J = 17.0, 4.0 1H), 2.92 (s, 3H) 2.60 (dqq, J = 10.8, 6.5, 6.5, 1H), 2.51–1.69 (m, 6H), 1.62 (s, 3H), 1.45 (s, 3H), 1.39 (s, 3H) 0.92 (d, J = 6.5, 3H), 0.60 (d, J = 6.5, 3H);  $\delta$  (minor conformer) [31/39 protons were discernable] 8.75 (br s, 1H), 7.09 (d, J = 8.0, 1H), 7.01 (d, J = 8.0, 1H), 6.97 (s, 1H), 6.22 (dd, J = 17.9, 10.3, 1H), 5.35 (J = 17.9, 1H), 5.33 (d, J = 11.0, 1H), 5.12–5.02 (m, 1H) 4.48–4.39 (m, 1H), 3.46 (dd, J = 11.0, 6.5, 1H), 3.39 (dd, J = 11.0, 6.5, 1H), 2.80 (dd, J = 15.0, 1.5, 1H), 2.73 (s, 3H), 2.39 (dqq, J = 11.0, 6.5, 6.5, 1H), 1.65 (s, 3H), 1.47 (s, 3H), 1.42 (s, 3H), 1.25 (d, J = 6.5, 3H), 0.94 (d, J = 6.5, 3H).

## References

- <sup>1</sup> Im, G-Y. J.; Bronner, S. M.; Goetz, A. E.; Paton, R. S.; Cheong, P.H.-Y.; Houk, K. N.; Garg, N. K. J. Am. Chem. Soc. **2010**, *132*, 1267–1269.
- <sup>2</sup> Igarashi, Y.; Yanagisawa, E.; Ohshima, T.; Takeda, S.; Aburada, M.; Miyamoto, K. *Chem. Pharm. Bull.* **2007**, *55*, 328–333.
- <sup>3</sup> Kauch, M.; Hoppe, D. Can. J. Chem. 2001, 79, 1736–1746.
- <sup>4</sup> Kauch, M.; Snieckus, V.; Hoppe, D. J. Org. Chem. 2005, 70, 7149-7158.
- <sup>5</sup> Griffen, E. J.; Roe, D. G.; Snieckus, V. J. Org. Chem. 1995, 60, 1484–1485.
- <sup>6</sup> Bronner, S. M.; Goetz, A. E.; Garg, N. K. J. Am. Chem. Soc. 2011, 133, 3832–3835.
- <sup>7</sup> Angelini, E.; Balsamini, C.; Bartoccini, F.; Lucarini, S.; Piersanti, G. J. Org. Chem. 2008, 73, 5654–5657.
- <sup>8</sup> Masuda, T.; Nakatsuka, S.-i.; Goto, T. Agric. Biol. Chem. 1989, 53, 2257-2260.
- <sup>9</sup> Moreno, O. A.; Kishi, Y. Bioorg. Med. Chem. 1998, 6, 1243-1254.
- <sup>10</sup> (a) Hama, T.; Liu, X.; Culkin, D. A.; Hartwig, J. F. J. Am. Chem. Soc. 2003, 125, 11176-
- 11177. (b) Liu, X.; Hartwig, J. F. J. Am. Chem. Soc. 2004, 126, 5182-5191.
- <sup>11</sup> Dobbs, A. J. Org. Chem. 2001, 66, 638–641.
- <sup>12</sup> Hama, T.; Culkin, D. A.; Hartwig, J. F. J. Am. Chem. Soc. 2006, 128, 4976–2985.
- <sup>13</sup> Moreno, O. A.; Kishi, Y. J. Am. Chem. Soc. **1996**, 118, 8180-8181.
- <sup>14</sup> Georg, G.; White, J.; Tunoori, A. J. Am. Chem. Soc. 2000, 122, 11995–11996.
- <sup>15</sup> (a) Muratake, H.; Natsume, M.; Okabe, K. *Tetrahedron* **1990**, *46*, 5113–5120. (b) Okabe, K.; Natsume, M. *Tetrahedron* **1991**, *47*, 7615–7624.
- <sup>16</sup> Webber, M. J.; Weston, M.; Grainger, D. M.; Lloyd, S.; Warren, S. A.; Powell, W. L.; Alanine, A.; Stonehouse, J. P., Frampton, C. S.; White, A. J. P.; Spivey, A. C. *Synlett* **2011**, *18*, 2693–2696.
- <sup>17</sup> Jelf, C. P.; Salmon, R. (Syngenta LTD, USA). Quinolin-, isoquinolin-, and quinazolinoxyalkylamides and their use as fungicides. US Patent 0,072,884, March 29, 2007.
- <sup>18</sup> Garg, N. K.; Caspi, D. D.; Stoltz, B. M. J. Am. Chem. Soc. 2005, 127, 5970–5978.
- <sup>19</sup> For a discussion on conformational analysis of indolactam alkaloids, see: (a) Endo, Y.; Hasegawa, M.; Itai, A.; Shudo, K.; Tori, M.; Asakawa, Y.; Sakai, S.-i. *Tetrahedron Lett.* **1985**,

26, 1069–1072. (b) Kawai, T.; Ichinose, T.; Endo, Y.; Shudo, K.; Itai, A. J. Med. Chem. 1992, 35, 2248–2253.

<sup>1</sup>H NMR Spectra:



































<sup>13</sup>C NMR Spectra:







F2 – Processing parameters SI 131072 SF 125.7577734 MHz WDW EM SSB 0 LB 1.00 Hz GB 0 PC 1.40 130-1 Current Data Parameters NAME smb-6-86f2c13b EXPNO 1 PROCNO 1 F2 – Acquisition Parameters Date\_\_\_\_20120420 2 34090.910 Hz 0.520186 Hz 0.9612446 sec 202.91 14.667 usec 18.00 usec 18.00 usec 2.0000000 sec 0.0300000 sec zgpg30 65536 CDCl3 = CHANNEL f1 = 13C 9.63 usec NISTRUM 14550 PULPROG 220030 TD 270536 SOLVENT 055536 SSLVENT 055536 SSLVENT 055236 DS 2523161 AQ 05672445 5 DW 14.667 use RG 14.667 use TE 236.0 K D1 0.03000000 st D1 2.0000000 st 0 0 PUC<sup>1</sup> шdd 9 18.380 19.665 21.664 20 25.973 28.742 30 33.064 - 34.162 6 50 840.88 -00 65.443 70 013.17 -80 8 778.86 -100 209.701 -110 971.911 -110,124 120 121.811 125.015 130 140 819.741 ----150 OTBS 160 170 - 172.690 т 24 180 Т ፳ <u>1</u>90 ě Be













